# Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma

> **NCT00753038** · PHASE2 · COMPLETED · sponsor: **Oncolytics Biotech** · enrollment: 14 (actual)

## Conditions studied

- Carcinoma, Squamous Cell of the Head and Neck

## Interventions

- **BIOLOGICAL:** REOLYSIN®
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT00753038
- **Lead sponsor:** Oncolytics Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2011-07
- **Final completion:** 2013-05
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2014-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00753038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00753038, "Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00753038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*